Interview with Trio Petroleum Corp. CEO, Frank Ingriselli
Trio Petroleum Corp. CEO Frank Ingriselli is Featured in an Interview with SmallCaps Daily
SmallcapsDaily Interview: Saagar Govil, CEO Cemtrex Inc.
SmallcapsDaily Interviews Cemtrex, Inc CEO Saagar Govil
Charge Enterprises: A Futuristic Small-Cap That Can Really ‘Power Up’ Your Portfolio
Charge Enterprises is a company that specializes in building infrastructure for electric vehicle charging and wireless networks. They offer a range of services including advising, designing, engineering, acquiring and installing equipment, monitoring, servicing and maintenance.
FORME Could Be The Next Powerhouse In The At-Home Fitness Industry
FORME (Nasdaq:TRNR) Just Completed an IPO and Could Become The Next Powerhouse In The At-Home Fitness Industry with a Differentiated Business Model Offering Premium Smart Home Gyms and Live Virtual Personal Training
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that the first patient has been screened for its...
Charge Enterprises, Inc. (NASDAQ: CRGE) Interview: Andrew Fox, CEO
Globally renowned serial entrepreneur with over two decades of experience in executing disruptive approaches to a wide range of industries including media, transportation, real estate, insurance, and consumer staples. Founded numerous companies with multiple successful exits, including Track Entertainment, WantTickets and Way Communications. Angel
investor in over 25 leading startups
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the ...